Drugs / STLX-2012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07231744 | Oct 2026 → Feb 2027 expected | — | Stelexis BioSciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STLX-2012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07231744 ↗ |
| Route | Intravenous | “single IV dose of STLX-2012” NCT07231744 ↗ |